Diverse stage-dependent effects of glucocorticoids in a murine model of viral myocarditis

Journal of Cardiology

Volumn 61, Issue 3, 2013, Pages 237-242

  Nakamura, Hiroshi ^a   Kunitsugu, Ichiro ^a   Fukuda, Keiichi ^b   Matsuzaki, Masunori ^a   Sano, Motoaki ^b  

^a YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KEIO UNIVERSITY   (Japan)

Author keywords

Cytokines; Drug therapy; Myocarditis; Prostaglandins; Viruses

Indexed keywords

ALPHA INTERFERON; DEXAMETHASONE; GLUCOCORTICOID; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; COXSACKIE VIRUS B3; DRUG EFFECT; FIBROSIS; HEART MUSCLE CELL; HEART PROTECTION; IMMUNOCOMPETENT CELL; INFLAMMATION; MOUSE; NONHUMAN; SURVIVAL; SYSTOLIC DYSFUNCTION; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS MYOCARDITIS;

ACUTE DISEASE; ANIMALS; COXSACKIEVIRUS INFECTIONS; CYCLOOXYGENASE INHIBITORS; DEXAMETHASONE; DISEASE MODELS, ANIMAL; ENTEROVIRUS B, HUMAN; GLUCOCORTICOIDS; MALE; MICE; MICE, INBRED STRAINS; MYOCARDITIS; NITROBENZENES; SULFONAMIDES; TIME FACTORS;

EID: 84875257973     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2012.11.006     Document Type: Article

References (16)

1. Mason J.W., O'Connell J.B., Herskowitz A., Rose N.R., McManus B.M., Billingham M.E., Moon T.E. A clinical trial of immunosuppressive therapy for myocarditis. N Engl J Med 1995, 333:269-275.
2. Parrillo J.E., Cunnion R.E., Epstein S.E., Parker M.M., Suffredini A.F., Brenner M., Schaer G.L., Palmeri S.T., Cannon R.O., Alling D., Wittes J.T., Ferrans V.J., Rodriguez E.R., Fauci A.S. A prospective, randomized, controlled trial of prednisone for dilated cardiomyopathy. N Engl J Med 1989, 321:1061-1068.
3. Kodama M., Okura Y., Hirono S., Hanawa H., Ogawa Y., Itoh M., Izumi T., Aizawa Y. A new scoring system to predict the efficacy of steroid therapy for patients with active myocarditis: a retrospective study. Jpn Circ J 1998, 62:715-720.
4. Moreels M., Delforge M.L., Renard M. Fulminant myocarditis with dramatic response to corticoids. Acta Cardiol 2010, 65:97-99.
5. Aziz K.U., Patel N., Sadulla T., Tasneem H., Thawerani H., Talpur S. Acute myocarditis: role of immunosuppression: a prospective randomised study. Cardiol Young 2010, 20:509-515.
6. 2 biosynthesis. J Clin Invest 2009, 119:1477-1488.
7. Shinmura K., Tang X.L., Wang Y., Xuan Y.T., Liu S.Q., Takano H., Bhatnagar A., Bolli R. Cyclooxygenase-2 mediates the cardioprotective effects of the late phase of ischemic preconditioning in conscious rabbits. Proc Natl Acad Sci U S A 2000, 97(10):197-202.
8. Timmers L., Sluijter J.P., Verlaan C.W., Steendijk P., Cramer M.J., Emons M., Strijder C., Gründeman P.F., Sze S.K., Hua L., Piek J.J., Borst C., Pasterkamp G., de Kleijn D.P. Cyclooxygenase-2 inhibition increases mortality, enhances left ventricular remodeling, and impairs systolic function after myocardial infarction in the pig. Circulation 2007, 115:326-332.
9. Dowd N.P., Scully M., Adderley S.R., Cunningham A.J., Fitzgerald D.J. Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo. J Clin Invest 2001, 108:585-590.
10. Takahashi T., Zhu S.J., Sumino H., Saegusa S., Nakahashi T., Iwai K., Morimoto S., Kanda T. Inhibition of cyclooxygenase-2 enhances myocardial damage in a mouse model of viral myocarditis. Life Sci 2005, 78:195-204.
11. Costanzo-Nordin M.R., Reap E.A., O'Connell J.B., Robinson J.A., Scanlon P.J. A nonsteroid anti-inflammatory drug exacerbates Coxsackie B3 murine myocarditis. J Am Coll Cardiol 1985, 6:1078-1082.
12. Takata S., Nakamura H., Umemoto S., Yamaguchi K., Sekine T., Kato T., Nishioka K., Matsuzaki M. Identification of autoantibodies with the corresponding antigen for the repetitive Coxsackievirus infection-induced cardiomyopathy. Circ J 2004, 68:677-682.
13. Nakamura H., Yamamura T., Fukuta S., Matsumori A., Matsuzaki M. A pathogenic mechanism of chronic ongoing myocarditis. Jpn Circ J 1996, 60:609-617.
14. Kohno T., Anzai T., Kaneko H., Sugano Y., Shimizu H., Shimoda M., Miyasho T., Okamoto M., Yokota H., Yamada S., Yoshikawa T., Okada Y., Yozu R., Ogawa S., Fukuda K. High-mobility group box 1 protein blockade suppresses development of abdominal aortic aneurysm. J Cardiol 2012, 59:299-306.
15. Nakamura H., Yamamura T., Umemoto S., Fukuta S., Shioi T., Matsumori A., Sasayama S., Matsuzaki M. Autoimmune response in chronic ongoing myocarditis demonstrated by heterotopic cardiac transplantation in mice. Circulation 1996, 94:3348-3354.
16. Kimura M., Ogawa H., Wakeyama T., Takaki A., Iwami T., Hadano Y., Mochizuki M., Hiratsuka A., Shimizu A., Matsuzaki M. Effect of mineralocorticoid receptor antagonist spironolactone on atrial conduction and remodeling in patients with heart failure. J Cardiol 2010, 57:208-214.